All News
Filter News
Found 84 articles
-
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors
6/10/2021
Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing.
-
BioSpace Movers & Shakers, April 23
4/23/2021
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
Lumen Bioscience Announces Appointment of Marcos Milla, Ph.D. to Board of Directors & Expansion of Leadership Team
4/22/2021
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Marcos Milla, Ph.D., to the company's board of directors and the expansion of its leadership team
-
Janux Therapeutics Appoints Charles Winter Senior Vice President of Chemistry, Manufacturing, and Controls
3/30/2021
Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Charles Winter as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC)
-
Targeted immunotherapy company Asher Bio launched today with a $55 million Series A round led by Third Rock Ventures, aiming to move its lead engineered interleukin-2 (IL-2) therapy into human testing next year.
-
Janux Therapeutics Appoints Vickie Capps and Dr. Sheila Gujrathi to Board of Directors
3/18/2021
Janux Therapeutics today announced the appointment of Vickie Capps and Sheila Gujrathi, M.D., as independent members of the Company’s Board of Directors.
-
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
2/10/2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors
-
Over the course of 2020, Sanofi saw significant growth in its specialty care sales primarily driven by its blue-chip asset, Dupixent, as well as an increase in vaccine sales that were driven by demand for differentiated influenza vaccines, the company announced in its year-end financial report.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Imago BioSciences Appoints Enoch Kariuki to Board of Directors
2/2/2021
Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that its board has appointed a new independent director, Enoch Kariuki, PharmD., who most recently served as the chief financial officer of VelosBio.
-
The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
-
Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some assets that will be key revenue drives for the company.
-
BioSpace Movers & Shakers, November 13
11/13/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer
11/10/2020
Silverback Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases, today announced the appointment of Jonathan Piaz
-
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
-
Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma
8/17/2020
Financial executives at wealth management advisory Oita Chuo Pacific Management have commented on Sanofi S.A. agreeing to acquire U.S. biotech firm Principia Biopharma Inc. in a deal worth $3.4 billion, as the French drug manufacturer shifts towards innovative treatments to boost growth under latest Chief Executive Officer Paul Hudson. According to data collected by Oita Chuo Pacific Management , the all-cash-deal will see
-
VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer
8/3/2020
VelosBio Inc . (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the appointment of Dr. Enoch Kariuki as Chief Financial Officer. Dr. Kariuki will lead all finance-related and investor relations functions at the Company. Dr. Kariuki is a highly accomplished finance executi
-
Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
7/29/2020
Sanofi (NASDAQ: SNY; EURONEXT: SAN) Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8751951-sanofi-earnings-results-q2-2020/ Q2 2020 sales results reflect the strong performance of Dupixent ® more than offset by COVID-19 related negative effects on Vaccines, General Medicines an
-
BioSpace Movers & Shakers, June 19
6/19/2020
Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Erasca Expands Leadership Team with Key Regulatory and Clinical Appointments
6/16/2020
Erasca, a company whose mission is to erase cancer, today announced the expansion of its leadership team with the appointment of Bao Truong as vice president of regulatory affairs and David Luo as vice president of clinical research and operations. “We are delighted to continue attracti